Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiya Horimoto

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|June 24, 2020
High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancerYoshiya Horimoto, Noriko Sasahara, Ritsuko Sasaki, et al.
BMC Cancer|July 31, 2014
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancerYoshiya Horimoto, Atsushi Arakawa, Masahiko Tanabe, et al.
Scientific Reports|May 17, 2018
Elucidation of inhibitory effects on metastatic sentinel lymph nodes of breast cancer during One-Step Nucleic Acid AmplificationYoshiya Horimoto, Masahiko Tanabe, Saiko Kazuno, et al.
Cancer Diagnosis & Prognosis|November 6, 2023
The Impact of Being Underweight on the Prognosis of Older Patients With Early Breast CancerYumiko Ishizuka, Yoshiya Horimoto, Midori Morita, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Attempt to Substitute the Oncotype DX Breast Recurrence Score<sup>®</sup> Test by Histopathological Factors and MUC1 Protein ExpressionYuka Nozaki, Yoshiya Horimoto, Ryoko Semba, et al.
Breast Cancer (Tokyo, Japan)|August 21, 2025
Sustained-release of 4-hydroxytamoxifen inhibits capsular contracture after breast implant placement in a mouse modelNozomi Matsumoto, Masako Muguruma, Yoshiya Horimoto, et al.
Medical Oncology (Northwood, London, England)|September 15, 2019
Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancerMayuko Ito, Yoshiya Horimoto, Emi Tokuda, et al.
Breast Cancer Research and Treatment|September 20, 2023
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancerYumiko Ishizuka, Yoshiya Horimoto, Hidetaka Eguchi, et al.
Molecular Cancer Therapeutics|April 27, 2011
ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistanceJulie Millour, Natalia de Olano, Yoshiya Horimoto, et al.
Breast Cancer (Tokyo, Japan)|January 15, 2022
Is adjuvant chemotherapy necessary in older patients with breast cancer?Midori Morita, Akihiko Shimomura, Emi Tokuda, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|June 24, 2020
High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancerYoshiya Horimoto, Noriko Sasahara, Ritsuko Sasaki, et al.
BMC Cancer|July 31, 2014
Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancerYoshiya Horimoto, Atsushi Arakawa, Masahiko Tanabe, et al.
Scientific Reports|May 17, 2018
Elucidation of inhibitory effects on metastatic sentinel lymph nodes of breast cancer during One-Step Nucleic Acid AmplificationYoshiya Horimoto, Masahiko Tanabe, Saiko Kazuno, et al.
Cancer Diagnosis & Prognosis|November 6, 2023
The Impact of Being Underweight on the Prognosis of Older Patients With Early Breast CancerYumiko Ishizuka, Yoshiya Horimoto, Midori Morita, et al.
Cancer Diagnosis & Prognosis|July 4, 2024
Attempt to Substitute the Oncotype DX Breast Recurrence Score<sup>®</sup> Test by Histopathological Factors and MUC1 Protein ExpressionYuka Nozaki, Yoshiya Horimoto, Ryoko Semba, et al.
Breast Cancer (Tokyo, Japan)|August 21, 2025
Sustained-release of 4-hydroxytamoxifen inhibits capsular contracture after breast implant placement in a mouse modelNozomi Matsumoto, Masako Muguruma, Yoshiya Horimoto, et al.
Medical Oncology (Northwood, London, England)|September 15, 2019
Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancerMayuko Ito, Yoshiya Horimoto, Emi Tokuda, et al.
Breast Cancer Research and Treatment|September 20, 2023
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancerYumiko Ishizuka, Yoshiya Horimoto, Hidetaka Eguchi, et al.
Molecular Cancer Therapeutics|April 27, 2011
ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistanceJulie Millour, Natalia de Olano, Yoshiya Horimoto, et al.
Breast Cancer (Tokyo, Japan)|January 15, 2022
Is adjuvant chemotherapy necessary in older patients with breast cancer?Midori Morita, Akihiko Shimomura, Emi Tokuda, et al.
Pageof 13